Basic Information
Fennec Pharma is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemoprotective agent for platinum-induced hearing loss. STS is being evaluated in two Phase III pediatric studies to assess reduction in ototoxicity and impact on survival.
Fennec Pharmaceuticals Inc.
NorthCarolina,United States of America
15~50 people
January 01, 1996
info@fennecpharma.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios